Central Trust Company’s Roivant Sciences ROIV Stock Holding History

Central Trust Company’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-146	Closed	-$4.04K	–	1661
2026 Q1	$4.04K	Buy	+146	New	+$3.75K	﹤0.01%	1290

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Central Trust Company's ROIV Position: Q2 2026 in Review

Central Trust Company sold out of Roivant Sciences (ROIV) in Q2 2026, closing a stake of 146 shares — an estimated $4.04K sold.

Central Trust Company first reported a position in ROIV in Q1 2026 and held it in 1 quarter. The position peaked at $4.04K in Q1 2026. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

Central Trust Company reported no remaining Roivant Sciences position as of Q2 2026 after selling out during the quarter.
Central Trust Company sold 146 Roivant Sciences shares in Q2 2026, an estimated $4.04K.
Central Trust Company first reported a position in Roivant Sciences in Q1 2026 and held it in 1 quarter.
Central Trust Company's Roivant Sciences position peaked at $4.04K in Q1 2026.
498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Central Trust Company's 13F filing for Q2 2026, filed 31 Jul 2026.